
Fortis Healthcare Limited has successfully completed the acquisition of a 31.52% equity stake in its material subsidiary, Agilus Diagnostics Limited, previously held by private equity investors. The transaction, announced on January 17, 2025, consolidates Fortis Healthcare’s ownership in Agilus Diagnostics to 89.2%.
Key Details of the Acquisition:
- Shares Acquired:
- 1,24,37,811 equity shares from NYLIM Jacob Ballas India Fund III LLC (NJBIF), representing a 15.86% equity stake.
- 63,10,315 equity shares from Resurgence PE Investments Limited, representing an 8.05% equity stake.
- Earlier, the company acquired 5,970,149 shares from International Finance Corporation (IFC), representing 7.61% equity stake.
- Total Stake Acquired:
- Combined, Fortis Healthcare has acquired 31.52% equity from the three PE investors.
- Post-Acquisition Stake:
- With this transaction, Fortis Healthcare now holds a majority stake of 89.2% in Agilus Diagnostics Limited.
This strategic move strengthens Fortis Healthcare’s position in the diagnostics segment by consolidating its control over Agilus Diagnostics, which is a key material subsidiary of the company.